Link Medicine has focused its research and development efforts in the field of autophagy, a process that clears and recycles misfolded proteins and has been developing potential new treatments for a range of diseases.
AstraZeneca disclosed it acquired multiple small molecule assets in clinical and preclinical stage that target the enzyme farnesyltransferase and modulate autophagy. Autophagy is an emerging area of research that can be applied to a range of diseases, including Parkinson’s and Alzheimer’s disease.
The agreement is the third for AstraZeneca’s new neuroscience Innovative Medicines Unit, which was established earlier this year. Under this new model, AstraZeneca is continuing to invest in neuroscience discovery research and early development for small and large molecules. Under the terms of the agreement, AstraZeneca will make specified upfront and milestone payments and will assume all of the program’s research and development activities. Financial terms were not disclosed.